ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
67.033,52
-0,07%
Brent Oil
83,76
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Arcturus Therapeutics Holdings Inc (ARCT)

  7. Arcturus Therapeutics Holdings Inc (ARCT) Notícias

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ARCT
DataHoraFonteTítuloCódigoCompanhia
15/05/202417:01Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202417:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202417:01Business WireArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/04/202417:01Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/03/202418:01Business WireArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/02/202411:00Business WireArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/02/202410:30Business WireArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
20/02/202411:00Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/02/202410:30PR Newswire (US)New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/12/202310:00Business WireCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/12/202310:00PR Newswire (US)CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/12/202322:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/12/202310:30Business WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202310:05PR Newswire (US)Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202310:00Business WireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/11/202311:13Dow Jones NewsArcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/11/202310:30Business WireArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/11/202310:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202318:01Business WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/10/202317:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/10/202309:30Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/09/202309:30Business WireArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/09/202309:30Business WireStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/09/202309:30Business WireArcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/08/202309:30Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/08/202310:00Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202317:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202317:01Business WireArcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/07/202317:01Business WireArcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ARCT

Seu Histórico Recente

EU
BE3062698209
Deutsche Bank Deutsche B...
NYSE
SYF-A
Synchrony Financiall
COIN
DYTEUST
Dynamite
BIT
P1JHT7
BNP Paribas Issuance
USOTC
ABOIF
Aboitiz Equity Ventures (PK)
NASDAQ
DPCS
DP Cap Acquisition Corpo...
COIN
DNSUST
BitDNS
NASDAQ
FOKHKX
FTP Dividend Strength Po...
ASX
FSFBN
COIN
PNDUSD
ASX
CWH
China West International
BIT
I09883
IT0005575094 20240902 20
BIT
UB4QCK
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados